What are the top Longevity Biotech startups by total funding raised?

Top startups in the Longevity Biotech Market ranked by total funding raised

Here is an updated table that ranks the top startups in the Longevity Biotech Market based on the total amount of funding they have raised to date.

The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).

If you need to dig deeper and get more detailed data, please check our report covering the Longevity Biotech Market.

Which longevity biotech startups have raised the most money?

The longevity funding leaderboard is dominated by a surprisingly small group: Eikon Therapeutics, Neko Health, NewLimit, BioAge Labs and CellCentric together account for just over half of all the capital in our 75-company dataset.

Using the reconstructed funding totals in the dataset, the 75 companies have raised roughly $8.4 billion in cumulative equity capital. Eikon sits first at about $1.5 billion, followed by Neko Health at $1.0 billion, NewLimit at $755 million, BioAge Labs at $624 million-plus and CellCentric at more than $470 million.

The amounts drop quickly after that. Function Health has raised about $351 million, Neurona Therapeutics $333 million, Human Longevity roughly $330 million, Juvenescence $295 million and Soley Therapeutics $290 million. By the time we reach the twentieth company, Amazentis/Timeline, cumulative funding is already down to roughly $66 million.

There is an important catch, though. These companies do not all mean the same thing by longevity. NewLimit is explicitly developing cellular rejuvenation medicines. Neko Health sells preventive body scans. Function Health combines diagnostic testing and health data. CellCentric is developing an epigenetic cancer drug. Eikon is primarily a drug-development company built around live-cell imaging. The ranking therefore measures capital raised across the wider longevity ecosystem rather than 75 interchangeable anti-aging drug developers.

Rank	Company	Approx. cumulative funding	Main model
1	Eikon Therapeutics	$1.5B	Drug development / live-cell imaging
2	Neko Health	$1.0B	Preventive health scanning
3	NewLimit	$755M	Epigenetic rejuvenation drugs
4	BioAge Labs	$624M+	Aging-biology therapeutics
5	CellCentric	$470M+	Epigenetic cancer therapeutics
6	Function Health	$351M	Preventive diagnostics
7	Neurona Therapeutics	$333M	Regenerative cell therapy
8	Human Longevity	$330M	Genomics / precision health
9	Juvenescence	$295M	Longevity therapeutics
10	Soley Therapeutics	$290M	Cell-stress drug discovery
11	Life Biosciences	$237M	Epigenetic rejuvenation
12	Loyal	$205M	Animal longevity drugs

Is Eikon Therapeutics really the most funded longevity biotech?

Eikon Therapeutics is the largest company in this dataset by cumulative financing, but calling it the world's most funded pure longevity biotech would stretch the definition too far.

Eikon has raised roughly $1.5 billion across private and public financing according to our reconstructed history. Its latest major financing was an upsized IPO that raised about $381 million in gross proceeds. The SEC prospectus confirms an $18 share price and approximately $381.2 million of gross IPO proceeds.

The problem is classification rather than financing. Eikon built a sophisticated live-cell imaging platform and uses it for drug discovery, but its clinical pipeline is primarily aimed at serious diseases including cancer. Longevity may benefit from better understanding cellular biology, yet Eikon is not trying to slow or reverse aging in the direct way NewLimit, Life Biosciences or Rubedo are.

Under a wide definition covering companies using advanced biology to tackle diseases strongly associated with aging, Eikon belongs near the top. Under a stricter definition requiring aging itself, cellular rejuvenation or healthspan to sit at the center of the business, Eikon probably falls outside the core group.

We would keep Eikon in a broad-market ranking, but we would not call it the best-funded dedicated longevity company.

Is Neko Health now the best-funded private longevity company?

Neko Health has become the largest privately funded company in the preventive-longevity part of this market, with roughly $1 billion raised after its enormous $700 million Series C.

That Series C changed the scale of Neko almost overnight. The company had already raised $260 million in its Series B, then added another $700 million led by Lightspeed Venture Partners and O.G. Venture Partners, with General Catalyst, Atomico, Lakestar and others participating.

The operating numbers help explain the size of the check. At the time of the financing, Neko said more than 100,000 people in Sweden and the UK had already undergone a scan and more than 350,000 had registered or joined the waiting list. It also said 75% of members booked and prepaid for their next scan before leaving their first appointment. Since then, Neko has opened in New York.

That makes Neko very different from a preclinical aging biotech. Investors are funding a healthcare service that already has consumers, physical locations and repeat usage.

So yes, Neko is now one of the best-funded private longevity companies under any broad definition of the market. It is better described as preventive health infrastructure than as an anti-aging biotech.

Is NewLimit the best-funded true rejuvenation biotech?

NewLimit is currently the strongest candidate for the title of best-funded private pure-play rejuvenation biotech, because its $755 million funding base is directly tied to reversing cellular aging.

The company raised a $435 million Series C led by Founders Fund, with Thrive Capital, Greenoaks, Quiet Capital and several existing investors participating. NewLimit said the money would help bring its first aging-reprogramming medicine into human trials.

NewLimit is not selling biological-age tests, supplements or preventive scans. Its core hypothesis is that epigenetic information in old cells can be changed so those cells regain younger function. The company is initially working on liver cells, while treating epigenetic reprogramming as a broader therapeutic platform.

Its fundraising is unusually large for a company that has not yet produced clinical efficacy data in humans. Roughly 58% of NewLimit's cumulative $755 million came from the latest Series C alone.

Among companies whose primary purpose is cellular rejuvenation rather than general healthcare, NewLimit stands apart. Life Biosciences has raised about $237 million, Shift Bioscience around $16 million-plus in our dataset, and other direct rejuvenation startups remain much smaller.

How concentrated is longevity biotech funding?

Longevity funding is extremely concentrated: roughly 71% of the capital in our 75-company dataset belongs to just ten companies.

Using the rounded cumulative amounts in the ranking, the full dataset adds up to around $8.4 billion. The top five account for approximately $4.35 billion, or 52%. Expanding to the top ten takes the total to roughly $5.95 billion, about 71%. The top twenty reach approximately $7.44 billion, close to 89%.

That leaves only about 11% of the observed capital spread across the remaining 55 companies.

Individual mega-rounds can therefore make the longevity market look much bigger from one year to another. Neko's $700 million Series C, NewLimit's $435 million Series C, Eikon's $381 million IPO, CellCentric's $220 million Series D and Soley's $200 million Series C alone represent nearly $1.94 billion.

A surge in total longevity funding does not mean hundreds of companies suddenly have easier access to money. A handful of companies can move the aggregate by billions while early-stage teams still compete for $5 million, $10 million or $20 million rounds.

Group	Approx. funding	Share of dataset total
Top 1 company	$1.50B	18%
Top 3 companies	$3.26B	39%
Top 5 companies	$4.35B	52%
Top 10 companies	$5.95B	71%
Top 20 companies	$7.44B	89%
Companies ranked 21–75	$0.95B	11%
All 75 companies	~$8.39B	100%

Which longevity startups have raised the biggest rounds recently?

The biggest recent longevity financings are now genuine mega-rounds: Neko raised $700 million, NewLimit $435 million and Eikon raised about $381 million through its IPO.

Neko's $700 million Series C is the standout private round. NewLimit followed with $435 million, while Eikon's IPO produced roughly $381 million in gross proceeds. CellCentric raised $220 million, Soley Therapeutics $200 million and BioAge's follow-on public offering ultimately generated about $132 million after the underwriters exercised their option.

Loyal's $100 million Series C, Tenpoint's $85 million Series B equity financing and Life Biosciences' $80 million Series D complete the group.

Tenpoint is a useful example of why round reconstruction matters. The headline transaction was $235 million, but $150 million was a credit facility. Only $85 million was Series B equity, so counting the whole headline number would overstate the startup's equity funding by almost three times.

Company	Recent equity financing	Type
Neko Health	$700M	Series C
NewLimit	$435M	Series C
Eikon Therapeutics	~$381M	IPO
CellCentric	$220M	Series D
Soley Therapeutics	$200M	Series C
BioAge Labs	~$132M	Public follow-on
Loyal	$100M	Series C
Tenpoint Therapeutics	$85M	Series B
Life Biosciences	$80M	Series D

Are investors putting more money into longevity drugs or preventive health?

Investors are backing both, but the very largest checks currently go to two different extremes: scalable preventive healthcare and high-conviction therapeutic platforms.

Neko's $700 million Series C and Function Health's $298 million Series B show how much money can now flow into consumer-facing preventive care. Function said its financing valued the company at $2.5 billion, after members had completed more than 50 million lab tests.

At the same time, NewLimit raised $435 million before entering human trials, CellCentric raised $220 million to advance pivotal multiple-myeloma studies, Soley raised $200 million for its cell-stress drug platform and Life Biosciences raised $80 million to finance clinical work on partial epigenetic reprogramming.

The middle is less obvious. Biomarker companies, supplements, smaller diagnostic platforms and early discovery startups commonly sit between $5 million and $50 million.

The two strongest funding stories right now are pretty different. One already has customers: give people more information about their bodies before they become sick. The other is scientifically ambitious: develop a drug or cell therapy capable of changing the biology behind age-related disease.

Generic wellness is in a weaker position unless it can show strong distribution, repeat customers or proprietary biology.

Are epigenetic reprogramming startups winning the longevity funding race?

Epigenetic rejuvenation has attracted some of the biggest conviction bets in longevity, although it has not yet produced the clinical evidence needed to say the technology has won.

NewLimit's $755 million cumulative funding is the clearest example. Life Biosciences has raised roughly $237 million and is also pursuing epigenetic restoration. General Control, 199 Biotechnologies and Shift Bioscience approach cellular aging from related reprogramming or gene-control directions at much earlier stages.

The gap between NewLimit and those smaller companies shows how selective investors have been. Capital is not flowing equally to every startup mentioning reprogramming. Most of it is concentrated in a few teams investors believe can turn the biology into controllable medicines.

Life Biosciences has moved further into the clinic. After securing $80 million, the company announced that the first patient had been dosed in its Phase 1 study of ER-100, its partial epigenetic reprogramming program for optic neuropathies.

Now the field needs human data. Until those trials produce interpretable safety and efficacy results, the huge financings around reprogramming remain bets on upside rather than evidence that rejuvenation has been clinically demonstrated.

How much funding has BioAge Labs raised, and what does its public-market financing tell us?

BioAge Labs has raised more than $600 million in cumulative financing in our reconstruction, making it one of the best-funded companies built explicitly around human aging biology.

BioAge is also unusual because it has crossed from private venture financing into public markets. Its latest follow-on offering produced approximately $132.3 million in gross proceeds after the overallotment option was fully exercised. BioAge said the financing, together with existing cash and marketable securities, should fund its current operating plan through 2029.

That makes BioAge a useful test of what happens when longevity science meets normal biotech capital markets. Investors can judge individual programs, clinical progress, cash burn and pipeline decisions rather than pricing the company mainly on the promise of discovering aging pathways.

BioAge also shows how longevity biotech can blur into mainstream drug development. The company studies aging biology, but it develops drugs against recognizable metabolic and age-related disease targets. If that model works, longevity may gradually become less of a standalone therapeutic category and more of a route to discovering targets across conventional disease areas.

Why did CellCentric raise $220 million if it is mainly a cancer biotech?

CellCentric raised $220 million because investors are financing a late-stage oncology asset with a plausible route to registration, even though the company's epigenetic biology also places it near the longevity ecosystem.

Its Series D was led by Venrock Healthcare Capital Partners with participation from Fidelity, Sofinnova, HBM Healthcare and existing investors including RA Capital, Forbion and Pfizer. CellCentric said the proceeds would fund registration-enabling trials of inobrodib in multiple myeloma.

Investors can evaluate CellCentric using oncology endpoints, clinical data and a defined regulatory pathway. That is a very different proposition from financing a speculative intervention designed to make people live longer.

This is why broad longevity rankings need interpretation. Epigenetic regulation is highly relevant to aging biology, but not every epigenetic drug is a longevity drug. CellCentric fits if the market includes companies exploiting biology linked to aging and age-related diseases. It is much harder to defend under a strict definition focused on slowing or reversing biological aging.

The $220 million round tells us more about the financeability of advanced clinical biotech than about investor enthusiasm for anti-aging itself.

Is Function Health becoming a longevity company or just a diagnostics platform?

Function Health increasingly looks like a preventive-health company built around lifelong health data, and that puts it firmly in the commercial side of longevity even though it is not a biotech drug developer.

Function raised a $298 million Series B and reached a reported $2.5 billion valuation. Its offering revolves around more than 160 laboratory tests, repeat testing, health-data interpretation and integrations with imaging and wearables. The company also acquired Ezra to add MRI and CT scanning to the platform.

The longevity connection comes from what Function is trying to sell: earlier detection, continuous measurement and better management of the risk factors that shape how long people stay healthy.

It is much easier to commercialize today than experimental rejuvenation medicine. People can already pay Function for testing; no breakthrough in aging biology needs to happen first.

Its $351 million cumulative financing shows that longevity capital is no longer restricted to laboratories trying to extend lifespan. Investors also see large businesses in helping healthy or mostly healthy people measure disease risk before symptoms appear.

Are whole-body scanning startups becoming a major part of longevity funding?

Whole-body scanning has become one of the best-funded commercial branches of longevity, led by Neko Health and Prenuvo.

Neko has raised about $1 billion and combines proprietary body scanning, blood testing and clinician interpretation. Prenuvo has raised roughly $176 million in our dataset and disclosed a $120 million Series B after surpassing 110,000 members.

Function Health adds another layer because it now combines laboratory testing with access to imaging following its acquisition of Ezra. Together, Neko, Prenuvo and Function account for more than $1.5 billion of cumulative financing in the dataset.

That is too much capital to treat preventive detection as a side branch of the longevity industry.

The business proposition is straightforward compared with experimental anti-aging drugs: detect cancer, cardiovascular risk or other disease earlier and people may gain healthy years even if nobody ever invents a pill that slows aging itself.

The scientific and clinical debates around broad screening remain important, but investors clearly see consumer demand for more intensive preventive medicine.

How much funding is going into animal longevity?

Animal longevity has moved well beyond a novelty niche, largely because Loyal has raised about $205 million to develop drugs intended to extend healthy lifespan in dogs.

Loyal's latest $100 million Series C is especially striking because it is larger than the total funding of most human longevity startups in our dataset. The company says the capital is being used to advance LOY-002 toward FDA approval.

Rejuvenate Bio adds another angle through gene therapies for age-related disease in companion animals. The company recently closed a $6 million financing alongside an R&D collaboration with Merck Animal Health.

The Cat Health Company is much smaller, with roughly $2 million raised, but its existence shows that the idea is spreading beyond dogs.

Animal longevity gives companies a way to pursue real regulatory products while learning about aging in mammals on shorter timelines than human lifespan studies would allow. Pet owners also already spend heavily on chronic disease and veterinary care.

Loyal's financing makes the scale of the opportunity pretty clear.

Which longevity startups are closest to proving their science in humans?

Life Biosciences, CellCentric, BioAge, Immunis, Pelage, Tenpoint and several other companies are much closer to clinical proof than the public image of longevity as mostly preclinical experimentation would suggest.

Life Biosciences has started first-in-human testing of its epigenetic restoration program. Immunis raised $25 million specifically to fund Phase 2 work in age-related muscle loss and metabolic dysfunction.

Pelage raised $120 million after Phase 2a work on PP405, which is designed to reactivate dormant hair-follicle stem cells, and said it expected to progress toward Phase 3 development.

CellCentric is advancing pivotal multiple-myeloma trials, while Tenpoint has already reached the commercial side of age-related eye care. These are very different interventions, but all have moved beyond simply showing an interesting molecular mechanism in a laboratory.

The sector now covers everything from newly funded discovery platforms to pivotal-stage products and commercial health services with large customer bases. Calling the whole thing preclinical no longer works.

Are smaller longevity biotechs still able to raise serious money?

Smaller longevity startups are still raising meaningful rounds, but the normal outcome is closer to $5 million–$20 million than to the headline $200 million–$700 million rounds.

Rapalogix raised $20 million to expand its longevity-focused skin-health platform. Revel Pharmaceuticals closed a $12 million seed round for enzymes intended to repair forms of molecular damage associated with aging. GlycanAge raised $8.7 million to expand glycan-based diagnostic testing.

Shift Bioscience raised $16 million for its AI-enabled cell-rejuvenation platform, bringing its disclosed total at the time to around $18 million.

These numbers are small beside Neko or NewLimit, but they are substantial for companies that may still be proving a platform, building an initial clinical package or validating commercial demand.

The early-stage market is still alive. The huge rounds are simply reserved for companies showing unusually strong scientific conviction, advanced clinical development or real commercial traction.

Is AI actually helping longevity startups raise more money?

AI is now common across longevity startups, but merely adding AI to an aging story does not appear to unlock exceptional funding on its own.

Soley Therapeutics is one of the biggest companies using computational methods in the field, with roughly $290 million raised and a $200 million Series C. Its pitch, however, is tied to a proprietary cell-stress platform and a concrete drug pipeline rather than AI alone.

Shift Bioscience uses machine learning to identify rejuvenation targets and raised $16 million in its large seed round. Gero, another AI-driven aging drug-discovery company, sits around the tens-of-millions level. EonArk is still smaller.

Juvenescence also combines longevity therapeutics with AI-enabled drug discovery and has attracted substantial funding, including a $76 million first close of its Series B-1 led by M42.

The pattern is fairly clear. AI can make a discovery platform more powerful and scalable, but investors still want biology, proprietary data, drug candidates or clinical progress. The biggest rounds are going to companies with something more defensible than an AI label.

Who are the most important investors backing longevity startups?

No single venture firm controls longevity investing, but a small group of specialist and generalist investors repeatedly appears around the strongest companies.

Founders Fund backs NewLimit and Gordian Biotechnology. Fidelity appears in CellCentric and Neurona. Khosla Ventures has backed both Viome and Rubedo. Hevolution has financed Rubedo and Vandria and appears across the wider longevity ecosystem. GV and ARCH co-led Pelage's $120 million Series B.

Other large names tend to appear around individual high-conviction bets: Lightspeed led Neko's Series C, Redpoint led Function Health's Series B, Venrock led CellCentric's Series D and M42 led Juvenescence's latest financing.

Repeated participation is more informative here than trying to rank investors by deployed dollars, because syndicate members rarely disclose exactly how much each contributed.

The mix is widening too. Traditional biotech funds, generalist growth investors, sovereign-backed healthcare groups, family capital and technology investors are all participating.

Investor	Examples in the dataset	What it suggests
Founders Fund	NewLimit, Gordian	High-risk aging biology
Hevolution	Vandria, Rubedo	Dedicated healthy-aging capital
Fidelity	CellCentric, Neurona	Later-stage biotech appetite
Khosla Ventures	Rubedo, Viome	Biology + unconventional health models
GV	Pelage	Regenerative medicine
ARCH Venture Partners	Pelage	Science-heavy biotech
Lightspeed	Neko Health	Preventive health at consumer scale
Redpoint	Function Health	Data-driven preventive health
M42	Juvenescence	Strategic longevity investment

Is longevity funding still mostly American?

The United States remains the center of gravity for large longevity financings, but the market is clearly international now.

NewLimit, BioAge, Function, Loyal, Pelage and many smaller therapeutic startups are based in the US. That gives the country a particularly deep combination of biotech talent, venture capital and access to public markets.

Capital is international too. Neko's syndicate spans US and European investors, while M42 from Abu Dhabi led Juvenescence's latest financing. Hevolution, established in Saudi Arabia, has become an important backer of aging science.

The US still has the deepest funding pool, but longevity is already a global capital market.

Are consumer-facing longevity businesses attracting biotech-sized rounds?

Yes. Neko Health and Function Health have shown that preventive-health companies can now raise rounds as large as serious late-stage biotechs.

Neko's $700 million Series C is larger than the latest rounds raised by NewLimit, CellCentric, Soley or Life Biosciences. Function's $298 million Series B is also larger than almost every therapeutic financing in the ranking.

Prenuvo has raised another $120 million in its Series B, while consumer-facing businesses such as OneSkin, Fountain Life, GlycanAge and Hone Health operate at smaller but still meaningful scales.

A drug company may spend years before generating product revenue, whereas a diagnostic membership, clinic or skincare business can begin charging customers much earlier. Investors get retention, revenue and demand signals without waiting for a Phase 2 trial.

That does not automatically make the consumer model better. Clinical longevity drugs could eventually address much larger disease markets. But for fundraising today, having customers helps a lot.

How big is the funding gap between longevity leaders and the long tail?

The funding gap is enormous: the tenth company has raised about $290 million, while more than half of the companies in the ranking have raised less than $25 million.

The twentieth-ranked company is already down to about $66 million. Around rank 35, funding falls to roughly $24 million. By the final dozen companies, cumulative financing is mostly in the $1 million–$7 million range.

This long tail matters because the sector contains dozens of genuinely interesting scientific approaches that have received only a fraction of the capital available to the leaders.

Cyclarity has raised around $24 million to target arterial plaque. Integrated Biosciences has about $17 million for AI and synthetic-biology approaches to aging. Refoxy sits near $12 million while developing FOXO3-related therapeutics. SENISCA has around $9 million for RNA-based approaches to cellular senescence.

That is enough capital to test ideas. It is nowhere near enough to finance multiple late-stage clinical programs without further rounds or partnerships.

Approx. rank	Company	Cumulative funding
1	Eikon Therapeutics	$1.5B
5	CellCentric	$470M+
10	Soley Therapeutics	$290M
20	Amazentis / Timeline	$66M+
30	Tolerance Bio	$32M
40	Integrated Biosciences	$17M
50	Stately Bio	$12M
60	Reservoir Neuroscience	$7M
70	ImmuneAGE Bio	$2M
75	Ora Biomedical	$1M

Which parts of longevity are investors funding less?

The least-funded areas tend to be scientifically early, narrowly targeted or difficult to commercialize quickly, rather than areas investors have completely abandoned.

Direct senescence-targeting companies remain relatively modest compared with the largest reprogramming or preventive-health businesses. Rubedo has raised about $52 million, SENISCA roughly $9 million and StarkAge around $1 million in our dataset.

Mitochondrial aging also remains smaller in financing terms. Vandria has raised around $31 million, while Yuva Biosciences sits near $8 million. Thymus-regeneration companies such as Tolerance Bio and TECregen are also still in the tens-of-millions rather than hundreds-of-millions range.

That does not tell us those approaches are scientifically weaker. Funding also depends on how quickly a company can reach clinical proof, how familiar the regulatory pathway is, how large the first commercial indication could be and whether the company already has human data.

The largest financings are clustering around platforms that investors believe can either become very large healthcare businesses or generate multiple valuable drug programs.

Are longevity investors moving toward companies with real clinical milestones?

Longevity funding increasingly rewards companies that can connect ambitious aging biology to conventional clinical milestones.

Life Biosciences is now dosing patients. Immunis is moving through Phase 2 development. Pelage used encouraging Phase 2a results to support a $120 million financing. CellCentric raised $220 million for pivotal work. Tenpoint has moved all the way into commercial-stage eye care.

NewLimit is an important exception because investors were willing to put $435 million behind epigenetic reprogramming before human clinical proof. Even there, the round was framed around getting its first rejuvenation medicine into human trials rather than indefinitely funding discovery.

The larger checks are increasingly tied to a very ordinary biotech question: what experiment will this money fund, and what result will tell us whether the product works?

That should make the sector much easier to evaluate over the next few years.

Does a huge funding round mean a longevity startup is more likely to win?

Huge funding helps enormously, but the ranking is a map of investor conviction rather than a ranking of scientific probability.

Neko's $1 billion financing base lets it open clinics and enter new markets much faster than smaller preventive-health companies. NewLimit can run expensive biology, manufacturing and clinical-development programs. CellCentric and Pelage can finance later-stage trials that would simply be impossible for a startup with $10 million.

Money changes what a company is capable of attempting.

It does not prove that an intervention works. A well-funded therapeutic program can fail in humans. A smaller company can discover something disproportionately valuable. Public-market financing can also push a company high in cumulative rankings long after the original venture thesis has changed.

The leaderboard tells us which strategies have earned the most financial backing. It does not tell us which products will extend human lifespan.

Why are some of the most funded “longevity” companies not really anti-aging companies?

Because the investable longevity market has expanded far beyond drugs designed explicitly to slow aging.

Eikon develops drugs using advanced cellular imaging. CellCentric is focused on cancer. Neurona develops regenerative cell therapies for neurological disease. Neko and Prenuvo try to detect disease earlier. Function measures health continuously. Pelage targets hair regeneration.

All of these businesses can influence healthspan, but only some attack aging biology directly.

The broad definition makes commercial sense because aging is the largest common risk factor behind many diseases, and companies rarely need regulatory approval for the abstract indication “aging.” They usually enter through cancer, neurodegeneration, metabolic disease, vision, muscle loss, dermatology or another defined condition.

For readers specifically interested in interventions designed to modify aging itself, NewLimit, Life Biosciences, Rubedo, Rejuvenate Bio, Oisín, Shift Bioscience, SENISCA and similar companies deserve more attention than their raw positions in the broad funding table might suggest.

Without that distinction, a $1 billion preventive-health business and a $20 million cellular-rejuvenation startup look like direct competitors when they really are not.

What does this funding ranking really say about the longevity biotech market today?

The longevity market is real and increasingly well funded, but the capital is concentrating around a handful of companies and several very different interpretations of what “longevity” actually means.

Our 75-company dataset contains roughly $8.4 billion in cumulative funding, yet about 71% belongs to the top ten companies and close to 89% belongs to the top twenty. The market is far more concentrated than a list of 75 funded startups initially suggests.

The biggest new checks also reveal what investors currently like. Neko and Function show strong appetite for preventive healthcare that can already generate usage and revenue. NewLimit shows that investors will still make exceptionally large bets on radical rejuvenation biology. CellCentric, Pelage, Life Biosciences and Immunis show that aging-related biology becomes easier to finance once it connects to concrete clinical programs.

Pure rejuvenation is only one part of the story. The market now stretches from epigenetic reprogramming and senescence therapies to diagnostics, imaging, regenerative medicine, animal health and consumer products.

If we narrow the question to dedicated rejuvenation biotechnology, NewLimit stands out as the best-funded private player. If we use the wider commercial definition of longevity, Neko has become the private funding heavyweight. Eikon remains the largest company in the full dataset, although its connection to longevity is much broader than NewLimit's or Life Biosciences'.

The sharpest conclusion is that investors are no longer debating whether longevity can attract serious capital. Billions of dollars have already moved into the space. The open question is which version of longevity will justify that capital: preventive healthcare, conventional drugs discovered through aging biology, or therapies that actually rejuvenate old cells.